LONDON, May 30, 2014 /PRNewswire/ --
The trading session on Thursday, May 29, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,698.74, up 0.39% and the NASDAQ Composite closed at 4,247.95, up 0.54%. The S&P 500 finished the day 0.54% higher at 1,920.03. The gains were broad based as nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index closed the day at 688.45, up 0.76%, and the index has advanced 2.45% in the previous one month. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Exelixis Inc. (NASDAQ: EXEL), Dendreon Corp. (NASDAQ: DNDN) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on ARNA, EXEL, DNDN and SGEN can be downloaded upon signing up at:
Shares in Arena Pharmaceuticals Inc. finished flat on Thursday, ending the day at previous day's closing price of $6.26. The stock recorded a trading volume of 2.53 million shares, much below its three months average volume of 5.47 million shares. The stock oscillated between $6.17 and $6.33 during the session. Over the previous three trading sessions and from the beginning of 2014, Arena Pharmaceuticals Inc.'s shares have gained 1.13% and 7.01%, respectively. However, the stock has edged lower by 0.48% in last one month. The company's shares are trading below their 50-day moving average. Arena Pharmaceuticals Inc.'s 50-day moving average of $6.38 is above its 200-day moving average of $6.10. Furthermore, the company's stock has a Relative Strength Index (RSI) of 44.37. Sign up today to read free research on ARNA at:
Exelixis Inc.'s stock finished Thursday's trading session 0.29% lower at $3.38. A total of 1.43 million shares were traded, much below its three months average volume of 5.01 million shares. The stock moved between $3.35 and $3.46 during the session. Exelixis Inc.'s stock has lost 1.74% in the previous three trading sessions and 44.86% since the start of this year, while it has traded flat in the last one month. The company's shares are trading below their 50-day and 200-day moving averages of $3.81 and $5.45, respectively. Further, Exelixis Inc.'s stock has an RSI of 43.73. Sign up today to read free research on EXEL at:
Shares in Dendreon Corp. recorded a trading volume of 1.40 million shares, which was below its three months average volume of 3.25 million shares. The stock ended the day at $2.21, which was 1.38% higher its previous day's closing of $2.18, and registered an intraday range of $2.17 and $2.24. However, shares in Dendreon Corp. have declined 0.45% in the previous three trading sessions, 12.65% in the last one month and 26.09% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $2.59 and $2.83, respectively. Additionally, shares of the company have an RSI of 41.02. Sign up today to read free research on DNDN at:
On Thursday, shares in Seattle Genetics Inc. fluctuated between $34.15 and $35.17 before ending the session 0.29% higher at $34.53. The company's stock reported a trading volume of 1.05 million shares, near its three months average volume of 1.17 million shares. Shares in Seattle Genetics Inc. have advanced 4.13% in the previous three trading sessions. However, the company's stock has lost 11.10% over the last one month and 13.44% on YTD basis. Seattle Genetics Inc.'s stock is trading below its 50-day and 200-day moving averages of $39.68 and $42.82, respectively. Moreover, the company's shares have an RSI of 43.25. Sign up today to read free research on SGEN at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.